Increased risk of open-angle glaucoma in non-smoking women with obstructive pattern of spirometric tests

Jihei Sara Lee¹,², Yong Joon Kim¹,², Sung Soo Kim³, Sungeun Park¹, Wungrak Choi³, Hyoung Won Bae¹ & Chan Yun Kim¹

To investigate differences in the prevalence of open-angle glaucoma (OAG) between different pulmonary function types. A population-based, cross-sectional analysis was conducted using Korean National Health and Nutrition Examination Surveys from 2008 to 2011. A total of 8941 subjects ≥ 40 years of age were analyzed. Chronic obstructive pulmonary disease (COPD) was defined as the ratio between first second of forced expiration (FEV1) and forced vital capacity (FVC) below 70%. The prevalence of glaucoma, as defined by the International Society of Geographical and Epidemiological Ophthalmology, was the main outcome. OAG was more prevalent in women with COPD (8.0% vs. 4.8% normal, P = 0.001) compared to women with normal pulmonary function. Intraocular pressure (IOP) of women with COPD were 13.3 (0.2) mmHg (13.9 (0.1) mmHg for normal function, P = 0.182). Never-smokers were more prevalent in women with COPD and glaucoma (92.9% vs. 52.4% normal function; P < 0.001). COPD was found to increase the risk of glaucoma in women (OR 2.077, P = 0.017) and even further in non-smoking women (OR 2.711, P = 0.003). Women with COPD showed a higher glaucoma prevalence despite similar IOP in comparison to women with normal pulmonary function. Non-smoking COPD is significantly associated with open-angle glaucoma in women.

Open-angle glaucoma (OAG) is a chronic progressive optic neuropathy which results in retinal ganglion cell death and structural change in the optic nerves. It remains one of the leading causes of irreversible blindness worldwide¹. As population is aging, glaucoma is becoming a growing public health concern², and identifying individuals at risk for early treatment is increasingly emphasized to prevent detrimental disability. Many studies to date have identified various risk factors: intraocular pressure (IOP), age, family history, migraine and cardiovascular diseases such as hypertension, just to name a few³,⁴. Identification of risk factors has not only allowed early treatment, but a greater insight into the pathogenesis of the disease.

Pulmonary conditions have received little attention so far as a risk factor, but there has consistently been evidence for their role in increasing the risk of OAG if not in the pathogenesis of OAG. For instance, obstructive sleep apnea has been postulated to accelerate structural progression of glaucoma⁵. Pulmonary hypertension has been established as a cause for secondary increase in IOP⁶. Furthermore, poor lung function may affect the posterior orbit and increase IOP⁷. Finally, hypoxia, lung hyperinflation, pulmonary vascular abnormality as well as negative impact on the contractility of the heart from chronic obstructive pulmonary disease (COPD) all amount to varying degrees of cardiovascular diseases, such as ischemic coronary disease, arrhythmia and heart failure⁸, and vascular diseases⁹ are a well-known risk factor for OAG. However, no studies to date have conducted a thorough analysis on the association between different pulmonary functions and glaucoma prevalence, especially obstructive lung disease and glaucoma. The availability of visual field test, fundus photography and spirometry results in Korean National Health and Nutrition Examination Survey (KNHANES) between 2008 and 2011 has allowed us to perform a population-based, cross-sectional analysis on this topic. The aim of this study was to identify the association between pulmonary functions and the prevalence of OAG.

¹Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. ²These authors contributed equally: Jihei Sara Lee and Yong Joon Kim. *email: kcyeye@yuhs.ac
Results

Baseline characteristics of study population. Of 37,753 subjects initially included in KNHANES from 2008 to 2011, a total of 8941 subjects (3902 men, 5039 women) were analyzed in this study (Fig. 1). Baseline characteristics of men and women according to the results of their pulmonary function test (PFT) are presented in Table 1. The obstructive group (62.6 ± 0.6 years old, men; 65.6 ± 1.0 years old, women) was generally older than the normal and restrictive groups for both men and women (restrictive 53.0 ± 0.8 years, normal 44.2 ± 0.3 years, P < 0.001 for men; restrictive 58.2 ± 1.1 years, normal 48.6 ± 0.3 years, P < 0.001 for women). While the majority of all six groups were never-smokers, the obstructive groups included higher proportions of self-reported never-smokers (73.6% vs. 51.3% normal function for men, 74.3% vs. 59.6% normal function for women) and lower proportions of ex-smokers (6.5% vs. 15.2% normal function for men; 6.9% vs. 13.0% normal function for women) than the normal groups.

Comparison of IOP and OAG prevalence. When average IOP was compared across the three groups, neither women nor men showed significant differences. Figure 2A illustrates the distribution of IOP for women. Women with COPD showed significantly lower IOP in comparison to women with normal function (P = 0.011). When women with glaucoma were singled out from each group and compared again, the weighted average between the three groups did not show a statistically significant difference, either (Fig. 2B). However, when the prevalence of OAG was calculated, men showed similar distribution of the disease across the three groups (8.3% obstructive vs. 8.1% normal; P = 0.966). In women, on the contrary, a significantly higher prevalence was noted in the obstructive group (8.0% vs. 4.8% normal; P = 0.001) in comparison to the other two groups (Table 1). According to our data review, none of the women diagnosed with glaucoma were on COPD medication. Among men with glaucoma, one was on COPD medication and another man had a previous history of COPD treatment.

Prevalence of never-smokers in women with glaucoma. The three groups were further divided into glaucoma and no glaucoma groups for comparisons. When the proportions of never-smokers in women were analyzed (Fig. 3), the normal and restrictive groups showed similar distribution of never-smokers between those with and without glaucoma (63.2% glaucoma vs. 59.4% no glaucoma, normal; 60.0% glaucoma vs. 61.0% no glaucoma, restrictive). However, in the obstructive group, never-smokers made up the majority of those with glaucoma, and the difference against women without glaucoma was statistically significant (82.6% vs. 73.6%, P = 0.005). The difference was found to be significant when the proportions were compared against women with glaucoma and restrictive lung function, as well as against those women with glaucoma and normal lung function (P < 0.001).
Association between OAG, smoking status and obstructive pulmonary disease in women. Logistic regression analyses were performed to identify associations between obstructive pulmonary disease and OAG (Table 2). Other than COPD, variables included in the analysis were the same parameters that were found to be significant risk factors of OAG from a previous study that employed the same data set of KNHANES. The analyses revealed that COPD was a significant risk factor for OAG in women when age, IOP, refractive status, BMI, HTN, smoking and exercise (OR 2.077, 95% CI 1.137–3.795, P = 0.017) were controlled.

Table 1. Baseline characteristics in men and women by pulmonary function. BMI body mass index, IOP intraocular pressure. Significant values are in bold. A P value < 0.05 was considered statistically significant.

| Table 1. Baseline characteristics in men and women by pulmonary function. BMI body mass index, IOP intraocular pressure. Significant values are in bold. A P value < 0.05 was considered statistically significant. |

| Demographic variables | Men (n = 3902) | Women (n = 5039) | P |
|-----------------------|----------------|------------------|---|
| Age, years            | 44.2 (0.3)     | 53.0 (0.8)       | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI, kg/m²             | 24.5 (0.1)     | 25.3 (0.2)       | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Health-related behavior | Smoking | | | | | | |
|-------------------------|---------|----------------|------------------|---|----------------|------------------|---|---|
| Age                     | 44.2 (0.3) | 53.0 (0.8) | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI                     | 24.5 (0.1) | 25.3 (0.2) | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Vigorous exercise       | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |
| Medical comorbidities   | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |

| Demographic variables | Men (n = 3902) | Women (n = 5039) | P |
|-----------------------|----------------|------------------|---|
| Age                   | 44.2 (0.3)     | 53.0 (0.8)       | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI                   | 24.5 (0.1)     | 25.3 (0.2)       | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Health-related behavior | Smoking | | | | | | |
|-------------------------|---------|----------------|------------------|---|----------------|------------------|---|---|
| Age                     | 44.2 (0.3) | 53.0 (0.8) | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI                     | 24.5 (0.1) | 25.3 (0.2) | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Vigorous exercise       | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |
| Medical comorbidities   | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |

| Demographic variables | Men (n = 3902) | Women (n = 5039) | P |
|-----------------------|----------------|------------------|---|
| Age                   | 44.2 (0.3)     | 53.0 (0.8)       | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI                   | 24.5 (0.1)     | 25.3 (0.2)       | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Health-related behavior | Smoking | | | | | | |
|-------------------------|---------|----------------|------------------|---|----------------|------------------|---|---|
| Age                     | 44.2 (0.3) | 53.0 (0.8) | 62.6 (0.6) | <0.001 | 48.6 (0.3) | 58.2 (1.1) | 65.6 (1.0) | <0.001 |
| BMI                     | 24.5 (0.1) | 25.3 (0.2) | 23.5 (0.1) | <0.001 | 24.0 (0.1) | 24.4 (0.2) | 23.5 (0.3) | 0.631 |

| Vigorous exercise       | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |
| Medical comorbidities   | 0–2 days/week | 2266 (84.3) | 380 (82.6) | 585 (77.5) | <0.001 | 3540 (82.7) | 397 (84.6) | 222 (77.1) | 0.002 |

Figure 2. Boxplot for comparison of IOP depending on pulmonary function in women (A) and among women with glaucoma (B). Comparisons of weighted estimates of average of IOP between the three groups showed that IOP was not different in women of different pulmonary function types (A, P = 0.182). When women with glaucoma were separately analyzed, no statistically significant difference was noted (B, P = 0.477).
Further analyses were conducted to find if smoking status affected the relationship between COPD and OAG (Table 3). While being a never-smoker alone was not associated with the risk of glaucoma, being a never-smoker with COPD more than doubled the risk of OAG (OR 2.711, 95% CI 1.405–5.232, P = 0.003) in women.
Discussion
In this study, we assessed nationwide, population-based data to identify association between pulmonary function and OAG. Our results demonstrated that OAG was more prevalent in women with COPD than those with restrictive or normal lung function despite similar IOP. COPD was found to increase the risk of OAG in women, and women with COPD were at even higher risks for OAG if they were never-smokers. To the best of our knowledge, our study is the first to identify non-smoking COPD as a risk factor for OAG in Korean women.

Literature on the association between COPD and glaucoma is scarce. The few existing studies have investigated the link between the two diseases in the context of adverse effects of medications. For instance, Huerta et al. found that the prevalence of airway disease was similar between the glaucoma cohort and the general population despite the risk of systemic absorption of beta-blocker eye drops. Another example is continuous and high-dose inhaled steroid, which has long been suspected to increase the risk of secondary glaucoma. A case-control study using the Quebec provincial health insurance plan concluded that the medication did not raise the risk of glaucoma or IOP. However, another study argued that higher doses and longer duration of inhaled corticosteroid for COPD were associated with a higher prevalence of glaucoma. To date, no studies have identified COPD, the disease itself, as an independent risk factor for OAG. We rule out the possibility of COPD medication affecting the prevalence of glaucoma in our study population as none of the women with glaucoma were on COPD medication prior to the spirometry test. There was, however, one man who were on COPD medication and another man with a previous history of COPD treatment at the time of the survey.

Factors that have been postulated to play important roles in the pathogenesis of OAG, in addition to high IOP, include alterations in nitric oxide and oxidative damage, hemodynamic abnormality and vascular factors. To that end, previous studies have implicated the role of COPD in propagating both oxidative stress and hemodynamic abnormality. For example, COPD is believed to share common risk factors as well as pathophysiological processes with cardiovascular diseases. Based on these findings, it is possible that COPD affects the prevalence of OAG through hemodynamic abnormality. There is also evidence for oxidative stress being a link between the two diseases. Lee et al. analyzed the KNHANES database and concluded that women with obstructive lung disease had significantly higher serum ferritin levels than women with normal spirometric results. A recent study that also analyzed the KNHANES data set demonstrated that serum ferritin is significantly greater in patients with glaucoma in comparison to control. The authors argued that their findings are associated with iron-related oxidative stress in OAG. These studies suggest that the accumulation of iron can cause degenerative damage in lungs as well as optic nerves. Although more extensive studies are needed, oxidative stress, including that caused by ferritin, may be another possible mechanism for the association between COPD and glaucoma.

Our study has identified women as a unique cohort that is substantially affected by the presence of COPD. In both COPD and OAG, women are increasingly found to experience a different course of disease in comparison to their male counterpart. For instance, women with COPD experience more frequent exacerbations, and acute exacerbations are thought to be followed by a period during which the likelihood of cardiovascular events is especially high. Women with COPD show a greater degree of local inflammatory response in the airways, and display higher levels of pro-inflammatory cytokines such as interleukin-16 in comparison to men. We speculate that such differences in the disease course for women may be associated with the differences in distribution of OAG depending on pulmonary function between men and women as demonstrated in our study.

According to the results of our study, having COPD increased the risk of OAG, but being a non-smoker with COPD increased the risk even more. Studies in the past couple of decades has suggested that non-smoking COPD is more prevalent than previously assumed. The pooled results of NHANES reported the prevalence of COPD in never-smokers to be 6.6%. A growing number of investigations have identified traits that distinguish non-smoker COPD from COPD, and these characteristics may explain why non-smoker COPD is more particulary associated with increased prevalence of OAG. For example, non-smoker COPD has shown higher rates of dyspnea and lower oxygen saturation than smoker COPD. Also, acute exacerbations are believed to be more frequent in non-smoker COPD. As mentioned above, the likelihood of cardiovascular events increases following acute exacerbations. During the episodes of exacerbations, more severe oxidative stress has been observed. Lastly, non-smoker COPD is believed to be predominantly female.

The effect of lung function on IOP has been investigated, but limited in scope. Variations in pleural pressure during spontaneous breathing in healthy subjects are believed to alter the volume of vascular beds of eyes. As far as intrathoracic pressure is concerned, the pressure is expected to rise in response to limited expiratory air flow in COPD, which may then decrease venous return from the head and elevate IOP in turn. In this regard, the results of comparison of IOP between the three groups was unexpected (Fig. 2). Our analysis showed that the mean IOP of women with obstructive lung function was lower than women with either normal or restrictive lung functions. The mechanism behind lower IOP in women with obstructive lung function is uncertain. We believe that the unanticipated results of our study are the proof that the effect of chronic lung disease on IOP in the long-term is different from that of transient changes in healthy individuals and that studies on the relationship between lung function and IOP are insufficient. Previous studies have revealed that abnormal lung-heart interaction triggers changes in sympathetic system, pulmonary and arterial reflexes, and it is possible that such altered relationships in COPD have unidentified effects on IOP. However, further in-depth studies are needed to describe how IOP and optic nerve respond to such complex interactions.

There are several limitations to this study. First, as our study was designed as a cross-sectional analysis, the results only support a significant association between the two diseases. Second, KNHANES utilized FDT instead of automated perimetric tests to assess visual field defects. Although FDT is ideal for large scale screenings, we suspect that the use of FDT may have resulted in overestimation of the number of individuals with glaucoma. In order to minimize overestimation, we excluded participants with a history of retinal disease and stroke, but it might have unintentionally excluded smokers, resulting in exaggerated proportions of never-smokers among...
those with COPD. Third, the number of individuals diagnosed with glaucoma by the ISGEO criteria were small in each group and may have affected the accuracy of the results. Lastly, the participants of this nationwide survey consist of a homogenous Asian population, among whom NTG is most prevalent. Therefore, cautions are advised when extrapolating these results to other populations.

In conclusion, the nationwide survey of a representative sample of Korean individuals showed that COPD increased the risk of OAG in women. The risk was even higher if COPD was present in never-smokers. Future prospective studies are necessary to confirm the role of COPD in the development of OAG and the mechanism with which the lung function affects the pathogenesis of glaucoma.

Methods

Study population. All analyses of this study were conducted on data obtained from KNHANES between 2008 and 2011. KNHANES is a cross-sectional, nationwide, population-based health examinations and survey that is carried out by the Korea Centers for Disease Control and Prevention with the approval from its Institutional Review Board. The study uses a stratified, multi-stage, clustered probability design to select a representative sample of non-institutionalized civilians among the Korean population. The study adhered to the Declaration of Helsinki and all involved participants provided written informed consent. The study consisted of health interviews, health behavior and nutrition survey and health examinations.

A total of 37,753 subjects were included in the KNHANES conducted between 2008 and 2011. Individuals 40 years or older were included in the analysis (Fig. 1). Participants with a self-reported history of stroke or retinal diseases were excluded from the analysis in order to minimize the risk of including visual field defects not associated with glaucoma. Retinal lesions were also excluded. Participants with shallow anterior chamber (as identified with gonioscopy during examinations) or signs of keratic precipitates were excluded. Those with a history of glaucoma treatment were excluded from the study in order to first eliminate possible effect of β-blocker and prostaglandins on the results of PFT, and second to identify possible differences in treatment-naive IOP depending on pulmonary function. When both eyes were eligible for inclusion, the right eye was selected. A total of 8941 individuals (3902 men, 5039 women) were subjected to analyses for this study. The study protocol was approved by the Institutional Review Board of Yonsei University Severance Hospital (Approval Number 4-2021-0654).

Ophthalmic survey. The protocol of ophthalmic examinations for the KNHANES has been described elsewhere41. In short, participants underwent visual acuity measurements, automated refraction, slit lamp examination, IOP measurement by trained ophthalmologists using a Goldmann applanation tonometer (Haag-Streit model BQ-900; Haag-Streit, Inc., Bern, Switzerland) and digital fundus photography (TRC-NW6S; Topcon, Inc., Tokyo, Japan, and Nikon, Inc., Tokyo, Japan). Peripheral anterior chamber depth was graded based on Van Herick’s criteria. Vertical cup-to-disc ratios (CDRs) and horizontal CDRs were determined based on the fundus photo images. Spherical equivalent refractive error was calculated as sphere + 1/2 cylinder. Participants additionally underwent visual field examination with frequency doubling technology (FDT) when they met any of the following criteria: (1) IOP ≥ 22, (2) horizontal or vertical CDRs ≥ 0.5, (3) violation of the ISNT rule, (4) optic disc hemorrhage, or (5) retinal nerve fiber layer (RNFL) defects. The FDT test was repeated if fixation errors or false-positive responses were greater than 33%. If a participant failed to respond below the 33% mark in the second test, the test was considered invalid. The diagnosis of glaucoma was made according to the modified International Society of Geographical and Epidemiological Ophthalmology (ISGEO) criteria. Category 1 required both a reliable visual field defect and glaucomatous optic disc (1) neuroretinal rim loss with vertical or horizontal CDR ≥ 0.6, (2) optic disc hemorrhage, (3) RNFL defects, or (4) asymmetry in vertical CDR ≥ 0.2. When FDT results were invalid or unavailable, category 2 was applied: (1) vertical CDR ≥ 0.9 (99.5th percentile), or (2) asymmetry of vertical CDR ≥ 0.3 (99.5th percentile). A defect was considered present if two different test points were abnormal.

Spirometric tests. Spirometry (Vmax 2130 Dry Rolling-seal Spirometer; SensorMedics, Yorba Linda, CA, USA) was conducted by four trained technicians. The test protocol followed the guidelines outlined by the American Thoracic Society/European Respiratory Society for standardizing the pulmonary function tests42. The tests that produced two acceptable spirometry curves (defined as curves which show the start of the test and expiration ≥ 6 s, show greatest differences between the two measurements of forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC) < 150 mL) were considered valid and included for the analysis. Participants were considered to have COPD if the ratio of FEV₁ to FVC (FEV₁/FVC) was below 70% according to the Global Initiative for Chronic Obstructive Lung Disease43. A restrictive lung disease was diagnosed if FEV₁/FVC ≥ 70% and FVC was < 80% predicted. Subjects were considered to have normal lung function if FEV₁/FVC ≥ 70% and FVC ≥ 80% predicted.

Statistical analysis. Statistical analyses were performed using SPSS statistical software (version 23; IBM Corporation, Armonk, NY). The PROC SURVEY procedure with sample weights was used to provide nationally representative prevalence estimates as recommended by the KNHANES, which employs complex sampling. The continuous variables were presented as mean (standard deviation) and the categorical variables were presented as number (percentage). Comparisons between groups were made using the Rao-Scott chi-square test (for categorical variables) or the Wald test (for continuous variables) as recommended. Simple and multivariate logistic regression analyses were conducted to identify association between the prevalence of OAG and obstructive lung disease. Participants with restrictive patterns were added to the normal group for regression analyses. The multivariate logistic regression model included as potential confounding variables those variables found to
be significant risk factors of OAG from a previous study that analyzed the same data set of KNHANES, namely age, gender, IOP, myopia, hypertension and BMI. Odds ratios (OR) and 95% confidence interval (CI) were calculated. For all analyses, the P-values were two-tailed and values < 0.05 were considered statistically significant.

Data availability
The data that support the findings of this study are available in Korean National Health and Nutrition Examination Surveys at https://knhanes.kdcac.go.kr/knhanes/main.do.

Received: 10 May 2022; Accepted: 23 September 2022
Published online: 08 October 2022

References
1. Pascolini, D. et al. 2002 global update of available data on visual impairment: A compilation of population-based prevalence studies. Ophthalmic Epidemiol. 11, 67–115. https://doi.org/10.1076/opei.11.2.67.28158 (2004).
2. Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2020 and 2040. Br. J. Ophthalmol. 90, 262–267. https://doi.org/10.1136/bjo.2005.081224 (2006).
3. Miglior, S. et al. Results of the European glaucoma prevention study. Ophthalmology 112, 366–375. https://doi.org/10.1016/j.ophtha.2004.11.030 (2005).
4. Leske, M. C. et al. Risk factors for incident open-angle glaucoma: The Barbados eye studies. Ophthalmology 115, 85–93. https://doi.org/10.1016/j.ophtha.2007.03.017 (2008).
5. Fan, Y. Y. et al. Correlation between structural progression in glaucoma and obstructive sleep apnea. Eye 33, 1459–1465. https://doi.org/10.1038/s41433-019-0430-2 (2019).
6. Lei, X. et al. Choroidal detachment and increased intraocular pressure in a case of secondary pulmonary hypertension. J. Glaucoma 28, e1–e4. https://doi.org/10.1097/JIG.0000000000001090 (2019).
7. Senthil, S., Kaur, B., Jalali, S. & Garudadri, C. Secondary open-angle glaucoma and central retinal vein occlusion in a patient with primary pulmonary hypertension. Ophthalmic Surg. Lasers Imaging 40, 50–53. https://doi.org/10.3926/15428877-20090101-18 (2009).
8. Falk, J. A. et al. Cardiac disease in chronic obstructive pulmonary disease. Proc. Am. Thorac Soc. 5, 543–548. https://doi.org/10.1513/pats.200708-142ET (2008).
9. Dursunoglu, N. et al. Severity of coronary atherosclerosis in patients with COPD. Clin. Respir. J. 11, 751–756. https://doi.org/10.1111/crj.12412 (2017).
10. Kim, K. E. et al. Prevalence, awareness and risk factors of primary open-angle glaucoma: Korea national health and nutrition examination survey 2008–2011. Ophthalmology 123, 532–541. https://doi.org/10.1016/j.ophtha.2015.11.004 (2016).
11. Huerta, C., Garcia Rodriguez, L. A., Moller, C. S. & Arellano, F. M. The risk of obstructive airways disease in a glaucoma population. Pharmacoepidemiol. Drug Saf. 10, 157–163. https://doi.org/10.1002/pds.56 (2001).
12. Gonzalez, A. V., Li, G., Sussa, S. & Ernst, P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm. Pharmacol. Ther. 23, 65–70. https://doi.org/10.1016/j.pupt.2009.10.014 (2010).
13. Nath, T. et al. Prevalence of steroid-induced cataract and glaucoma in chronic obstructive pulmonary disease patients attending a tertiary care center in India. Asia Pac. J. Ophthalmol. 6, 28–32. https://doi.org/10.22608/APO.201616 (2017).
14. Shen, F. et al. Glutamate-induced glutamine synthetase expression in retinal Muller cells after short-term ocular hypertension in the rat. Investig. Ophthalmol. Vis. Sci. 45, 3107–3112. https://doi.org/10.1167/iovs.03-0948 (2004).
15. Galassi, F. et al. Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br. J. Ophthalmol. 88, 757–760. https://doi.org/10.1136/bjo.2003.028357 (2004).
16. Chung, H. S. et al. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv. Ophthalmol. 43(Suppl 1), S43-50. https://doi.org/10.1007/s00417-000-0505-8 (1999).
17. Lee, S. H. et al. Vascular and metabolic comorbidities in open-angle glaucoma with low- and high-normal intracocular pressure: A cross-sectional study from South Korea. Acta Ophthalmol. 95, e564–e574. https://doi.org/10.1111/doi.13487 (2017).
18. Baum, C. et al. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int. J. Cardiol. 218, 298–304. https://doi.org/10.1016/j.ijcard.2016.05.034 (2016).
19. Lipworth, B. et al. Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease. Heart 102, 1909–1914. https://doi.org/10.1136/heartjnl-2016-309458 (2016).
20. Vosib, I. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet 387, 1817–1826. https://doi.org/10.1016/S0140-6736(16)30069-1 (2016).
21. Lee, C. H. et al. Association of serum ferritin levels with smoking and lung function in the Korean adult population: Analysis of the fourth and fifth Korean national health and nutrition examination survey. Int. J. Chron. Obstr. Pulm. Dis. 11, 3001–3006. https://doi.org/10.2147/COPD.S116982 (2016).
22. Lin, S. C., Wang, S. Y., Yoo, C., Singh, K. & Lin, S. C. Association between serum ferritin and glaucoma in the South Korean population. JAMA Ophthalmol. 134, 1414–1420. https://doi.org/10.1001/jamaophthalmol.2014.2876 (2014).
23. Chen, H. et al. Changes in iron-regulatory proteins in the aged rodent neural retina. Neurobiol. Aging 30, 1865–1876. https://doi.org/10.1016/j.neurobiolaging.2008.01.002 (2009).
24. Aquino, D. et al. Age-related iron deposition in the basal ganglia: Quantitative analysis in healthy subjects. Radiology 252, 165–172. https://doi.org/10.1148/radiol.2522081399 (2009).
25. Altamura, S. & Muckenthaler, M. U. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 16, 879–895. https://doi.org/10.3233/JAD-2009-1010 (2009).
26. Kell, D. B. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genom. 2, 2. https://doi.org/10.1186/1755-4794-2-2 (2009).
27. de Torres, J. P., Cansano, C., Montejo de García, A., Aguino-Iaine, A. & Celli, B. R. Gender and respiratory factors associated with dysnea in chronic obstructive pulmonary disease. Respir. Res. https://doi.org/10.1186/1465-9921-8-18 (2007).
28. Donaldson, G. C., Hurst, J. R., Smith, C. J., Hubbard, R. B. & Wedzicha, J. A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 137, 1091–1097. https://doi.org/10.1378/chest.09-2029 (2010).
29. Gut-Gobert, C. et al. Women and COPD: Do we need more evidence?. Eur. Respir. Rev. https://doi.org/10.1183/16000617.0055-2018 (2019).
30. de Torres, J. P. et al. Gender differences in plasma biomarker levels in a cohort of COPD patients: A pilot study. PLoS ONE 6, e16021. https://doi.org/10.1371/journal.pone.0016021 (2011).
31. Salvi, S. S. & Barnes, P. J. Chronic obstructive pulmonary disease in non-smokers. Lancet 374, 733–743. https://doi.org/10.1016/S0140-6736(09)61303-9 (2009).
32. Behrendt, C. E. Mild and moderate-to-severe COPD in nonsmokers: Distinct demographic profiles. *Chest* **128**, 1239–1244. https://doi.org/10.1378/chest.128.3.1239 (2005).
33. Meneghini, A. C. *et al.* Biomass smoke COPD has less tomographic abnormalities but worse hypoxemia compared with tobacco COPD. *Braz. J. Med. Biol. Res.* **52**, e8233. https://doi.org/10.1590/1414-431X20198233 (2019).
34. Jindal, S. K. *et al.* COPD exacerbation rates are higher in non-smoker patients in India. *Int. J Tuberc. Lung Dis.* **24**, 1272–1278. https://doi.org/10.5588/ijtld.20.0253 (2020).
35. Drost, E. M. *et al.* Oxidative stress and airway inflammation in severe exacerbations of COPD. *Thorax* **60**, 293–300. https://doi.org/10.1136/thx.2004.027946 (2005).
36. Buist, A. S. *et al.* International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. *Lancet* **370**, 741–750. https://doi.org/10.1016/S0140-6736(07)61377-4 (2007).
37. Bridevaux, P. O. *et al.* Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. *Eur. Respir. J.* **36**, 1259–1269. https://doi.org/10.1183/09031936.0004110 (2010).
38. Lundmark, P. O., Trope, G. E. & Flanagan, J. G. The effect of simulated obstructive apnoea on intracranial pressure and pulsatile ocular blood flow in healthy young adults. *Br. J. Ophthalmol.* **87**, 1363–1369. https://doi.org/10.1136/bjo.87.11.1363 (2003).
39. Forfia, P. R., Vaida, A. & Wiegens, S. E. Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes. *Pulm. Circ.* **3**, 5–19. https://doi.org/10.4103/2045-8932.109910 (2013).
40. Andre, S. *et al.* COPD and cardiovascular disease. *Pulmonology* **25**, 168–176. https://doi.org/10.1016/j.pulmo.2018.09.006 (2019).
41. Lee, S. H. *et al.* Estimated trans-lamina cribrosa pressure differences in low-teen and high-teen intracranial pressure normal tension glaucoma: The Korean national health and nutrition examination survey. *PLoS ONE* **11**, e0148412. https://doi.org/10.1371/journal.pone.0148412 (2016).
42. Miller, M. R. *et al.* Standardisation of spirometry. *Eur. Respir. J.* **26**, 319–338. https://doi.org/10.1183/09031936.05.000340 (2005).
43. Vestbo, J. *et al.* Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am. J. Respir. Crit. Care Med.* **187**, 347–365. https://doi.org/10.1164/rccm.201204-0596PP (2013).

**Author contributions**

J.S.L. wrote the main manuscript text and prepared figures; Y.J.K. and J.S.L. conducted statistical analyses; C.Y.K. provided administrative, technical and material support; all authors provided critical revision of the manuscript for important intellectual content. All authors reviewed the manuscript.

**Funding**

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (No. NRF-2019 R1A2C1091089). The funding organization had no role in the design or conducting of this research. None of the authors have any commercial or proprietary interests in any of the instruments or materials described in this study.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to C.Y.K.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022